Government Pharmaceutical Organisation (GPO)
Government Pharmaceutical Organisation (GPO) is Thailand's state-owned pharmaceutical manufacturer under the Ministry of Public Health. FY2024 revenue approximately THB 16B. Operates under statutory mandate to ensure domestic drug security, essential-medicines access at affordable prices. Product portfolio: generic essential medicines (NLEM-listed formulations), Thailand's primary HIV antiretroviral (ARV) producer, growing biosimilar portfolio in development, plus Strategic Stockpile custodian for pandemic, emergency response. Not tradable (state enterprise) but materially shapes market pricing, drug availability.
Snapshot
Headline numbers a buyer checks first.
FY2024 revenue
~THB 16B
FY2024
Status
State enterprise (MoPH)
Ongoing
Role
Generics, HIV ARV, biosimilar
FY2024
Founded
1966
Historical
What this organisation actually does
GPO manufactures, supplies essential medicines to Thailand's public health system under MoPH mandate. Core production: NLEM-listed generic formulations (cardiovascular, diabetes, antibiotics, oncology supportive care), Thailand's primary domestic HIV ARV manufacturer (achieving ARV self-sufficiency via generic production), expanding biosimilar pipeline (erythropoietin, filgrastim, trastuzumab candidates). GPO operates Strategic Stockpile for pandemic, emergency response, which was materially expanded during COVID-19. Distribution channels: MoPH central procurement, direct UCS, public-hospital supply, retail-pharmacy secondary channel.[]
Strategic position: GPO is the backbone of Thai domestic drug security. Competitive dynamics: GPO wins UCS, public-hospital procurement via NLEM-listed supply but does not compete on patented or novel specialty products. MNC originator subsidiaries, GPO operate in complementary rather than competing segments. Policy pressure: GPO expected to expand biosimilar, biologic capability over 2025-2030 as Thailand pursues reduced import dependence; capital, technology investment pace is the binding variable.[, ]
Programs administered
Essential medicines
NLEM generic manufacturing
GPO produces NLEM-listed generic formulations for cardiovascular, diabetes, antibiotics, and oncology-support. FY2024 production covers ~80% of essential-medicine categories on Thailand's National List. Distribution via MoPH central procurement.
HIV/ARV
Antiretroviral self-sufficiency programme
Thailand achieves 95% ARV self-sufficiency through GPO generic production under TRIPS-compliant compulsory-licensing framework. GPO is the primary domestic manufacturer of NNRTI and NRTI combinations for the national HIV treatment programme.
Biosimilars
Biosimilar development pipeline
GPO has biosimilar candidates for erythropoietin (EPO), filgrastim (G-CSF), and trastuzumab in development. WHO prequalification is the gateway to replacing costly originator biologics in public-hospital formularies.
Emergency
Strategic Stockpile, cannabis extract
GPO maintains Thailand's Strategic Stockpile β ~6-month buffer for essential medicines, antivirals, PPE. Also holds exclusive state licence for medical cannabis extract manufacturing under current MoPH regulatory framework.
GPO product portfolio and market role
Generic essential medicines (NLEM)
GPO role
Primary domestic manufacturer, MoPH central procurement
Market significance
Ensures price floor on essential drugs; MNC originators compete on branded generics
HIV antiretrovirals (ARV)
GPO role
Primary domestic ARV manufacturer (GPE ARV)
Market significance
Thailand achieves 95% ARV domestic self-sufficiency via GPO generic programme
Biosimilars (EPO, filgrastim)
GPO role
Developing capability; EPO, filgrastim in pipeline
Market significance
If WHO prequalified, GPO biosimilars could compete with imported originator biologics in public system
Medical cannabis extract
GPO role
Sole authorised Thai state producer (GPO exclusive)
Market significance
GPO holds extraction monopoly under current regulatory framework; MoPH clinical supply
Strategic Stockpile
GPO role
Custodian; PPE, antivirals, vaccine stock
Market significance
Post-COVID expansion; ~6-month buffer for essential medicines across public hospital system
| Product category | GPO role | Market significance |
|---|---|---|
| Generic essential medicines (NLEM) | Primary domestic manufacturer, MoPH central procurement | Ensures price floor on essential drugs; MNC originators compete on branded generics |
| HIV antiretrovirals (ARV) | Primary domestic ARV manufacturer (GPE ARV) | Thailand achieves 95% ARV domestic self-sufficiency via GPO generic programme |
| Biosimilars (EPO, filgrastim) | Developing capability; EPO, filgrastim in pipeline | If WHO prequalified, GPO biosimilars could compete with imported originator biologics in public system |
| Medical cannabis extract | Sole authorised Thai state producer (GPO exclusive) | GPO holds extraction monopoly under current regulatory framework; MoPH clinical supply |
| Strategic Stockpile | Custodian; PPE, antivirals, vaccine stock | Post-COVID expansion; ~6-month buffer for essential medicines across public hospital system |
Key drivers 2025-2026
Biosimilar pipeline, NLEM inclusion
GPO biosimilars entering WHO prequalification; NLEM formulary additions reduce import dependency.
Strategic Stockpile expansion
Post-COVID pandemic-preparedness funding, emergency-medicine buffer expansion.
Capital, GMP upgrade investment
Manufacturing-facility modernisation, WHO prequalification pursuit pace.
MoPH procurement alignment
Central-procurement budget cycle, NLEM product-mix decisions.
Watchpoints
Biosimilars
WHO prequalification milestone
GPO's biosimilar pipeline (EPO, filgrastim, trastuzumab candidates) requires WHO PQ certification to replace originator biologics in public-hospital formularies. Any PQ approval materially reduces Thailand's biologic import bill.
Policy
MoPH procurement budget allocation
GPO's revenue is structurally linked to MoPH central-procurement budget cycles. Annual budget allocation to UCS drug procurement determines GPO's volume offtake. Watch MoPH Annual Budget Act filings for NLEM-procurement envelope.
Capacity
GMP manufacturing upgrade pace
GPO's Rangsit facility requires ongoing GMP upgrades to maintain Thai FDA and international certification. Capital-investment pace determines whether GPO can expand into new product categories or maintain current essential-medicine output.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
Mega Lifesciences
Largest listed Thai pharma; complementary rather than direct competitor.
Open Market profile β
Competitor
Siam Pharmaceutical
Leading private generics manufacturer.
Open Market profile β
Sector peer
Government Pharmaceutical Organization (GPO)
Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.
Open Market profile β
Sector peer
GSK Thailand
UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.
Open Market profile β
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
Government Pharmaceutical Organisation (GPO) β Annual Report, Product Catalogue
National List of Essential Medicines (NLEM) β Committee, Pricing
Publisher
Ministry of Public Health, Drug Subcommittee
Grade
Primary
As of
2025-12-31
| Source | Publisher | Grade | As of |
|---|---|---|---|
| Government Pharmaceutical Organisation (GPO) β Annual Report, Product Catalogue | Government Pharmaceutical Organisation | Primary | 2026-02-28 |
| National List of Essential Medicines (NLEM) β Committee, Pricing | Ministry of Public Health, Drug Subcommittee | Primary | 2025-12-31 |
Reports featuring this profile
Thailand Cannabis & Hemp Industry Market Intelligence
State-owned medical cannabis oil producer
Open report β
Sits alongside 3 other Atlas profilesThailand Pharmaceuticals Market Intelligence
State pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.
Open report β
Sits alongside 7 other Atlas profilesThailand Medical Cannabis & CBD Market Intelligence
GPO holds Thai medical cannabis extract manufacturing state monopoly.
Open report β
Sits alongside 4 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
GPO state manufacturer, NLEM generics, sole medical cannabis extract producer.
Open report β
Sits alongside 7 other Atlas profilesThailand Life Sciences, Biotech, GPO BioPharm Deep Dive
GPO β state generic, vaccine, biosimilar manufacturer
Open report β
Sits alongside 3 other Atlas profiles